The primary outcome variable in trials at the onset of type 1 diabetes is preservation of C-peptide. GAD65 is a prominent target of the autoimmunity of humans, with GAD65 autoantibodies one of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback